Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Advertisement

Advertisement




Sep
03
Today In Oncology
MD Anderson President Announces Retirement, Shares Leadership Transition Plans
ASCENT-04 Exploratory Analysis: Sacituzumab Govitecan Plus Pembrolizumab Improves PFS2, Delays Next Treatment
Spartalizumab-Based Triplet Improves Long-Term Overall Survival in BRAF V600–Mutant Melanoma
Sociological Study Explores the Concept of ‘Temporal Misalignment’ Among Patients With Terminal Cancer
High-Risk Prostate Cancer GETUG-AFU 18 Suggests a Role for Dose-Escalated Radiotherapy With Long-Term ADT
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo